The rounds this investor is named on, who it invests beside, and where it shows up.
Named on 23 rounds in the feed, most often at Series A and in Biotech.
Foresite Capital is a multi-stage healthcare and life sciences investment firm addressing areas of great unmet need by funding promising businesses at all stages of their life cycles.
Venture capitalforesitecapital.comRounds from 2017-09-18 to 2026-10-01
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
KymaThera A provider of precision medicines for genetically defined diseases | Series B Verified against 1 of 14 sources | $80M | 2026-10-01 | [ PART ] |
Thyme Care Thyme Care enhances the cancer journey with expert oncology navigation and an oncology care team, partnering to improve access, outcomes, and costs. | Series E Verified against 4 of |
| $125M |
| 2026-09-02 |
| [ PART ] |
Abcuro Breakthrough therapies for autoimmune diseases and cancer for patients with specific conditions. | Series D Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $66M | 2026-08-18 | [ PART ] |
Stepful Stepful trains people for healthcare jobs, combining AI-supported learning with local hands-on training. | Series C Verified against 1 of 7 sources[ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $55M | 2026-06-08 | [ PART ] |
Slate Medicines Next-generation therapeutics for migraine and headache disorders targeting pathways involved in migraine pathophysiology. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $130M | 2026-02-24 | [ LEAD ] |
Korsana Korsana develops advanced therapeutics aimed at treating neurodegenerative diseases, particularly focusing on Alzheimer's disease. | Series A Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $150M | 2026-02-18 | [ PART ] |
Midi Health Joinmidi sells virtual healthcare services and hormonal care products specifically focused on women's health, including treatments and personalized care plans for menopause and related symptoms. | Series D Verified against 3 of 9 sources[ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $100M | 2026-02-03 | [ PART ] |
Thyme Care Thyme Care enhances the cancer journey with expert oncology navigation and an oncology care team, partnering to improve access, outcomes, and costs. | Series D Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $97M | 2025-09-25 | [ PART ] |
Latigo Biotherapeutics Latigo is a clinical-stage biopharmaceutical company developing innovative non-opioid pain medicines. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $150M | 2025-03-17 | [ PART ] |
Eikon Therapeutics Eikon is a late-stage clinical biopharmaceutical company focused on inventing and developing breakthrough therapeutics for serious illnesses through innovative scientific and engineering approaches. | Series D Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $350.7M | 2025-02-26 | [ PART ] |
Abcuro Breakthrough therapies for autoimmune diseases and cancer for patients with specific conditions. | Series C Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $200M | 2025-02-12 | [ PART ] |
Xaira Therapeutics Xaira Therapeutics sells AI-driven solutions to accelerate drug discovery and development, targeting biopharmaceutical companies and healthcare providers. | Funding round Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $1.0B | 2024-04-24 | [ LEAD ] |
Latigo Biotherapeutics Latigo is a clinical-stage biopharmaceutical company developing innovative non-opioid pain medicines. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $135M | 2024-02-14 | [ LEAD ] |
Odyssey Odyssey Therapeutics develops innovative therapies aimed at transforming the treatment of autoimmune and inflammatory diseases for patients. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $168M | 2022-10-13 | [ PART ] |
Eikon Therapeutics Eikon is a late-stage clinical biopharmaceutical company focused on inventing and developing breakthrough therapeutics for serious illnesses through innovative scientific and engineering approaches. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $517.8M | 2022-01-06 | [ PART ] |
bit.bio A human cell programming company developing technology to produce consistent, scalable human cell models for drug discovery, disease research, functional genomics and toxicology. | Series B Verified against 2 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $103M | 2021-11-05 | [ PART ] |
Eikon Therapeutics Eikon is a late-stage clinical biopharmaceutical company focused on inventing and developing breakthrough therapeutics for serious illnesses through innovative scientific and engineering approaches. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $148M | 2021-05-05 | [ PART ] |
Inscripta Biomanufacturing solutions that replace traditional fossil-based ingredients and products. | Series E Verified against 1 of 5 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $150M | 2021-04-05 | [ PART ] |
LifeMine LifeMine is a clinical-stage biopharmaceutical company that develops next-generation precision medicines through an innovative drug discovery approach focused on evolutionary insights from fungi, targeting patients in need of breakthrough therapies. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $50M | 2021-01-07 | [ PART ] |
bit.bio A human cell programming company developing technology to produce consistent, scalable human cell models for drug discovery, disease research, functional genomics and toxicology. | Series A Developing, 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $41.5M | 2020-06-13 | [ PART ] |
Kriya Therapeutics Kriya Therapeutics develops durable medicines aimed at treating chronic diseases with one-time administration. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $80.5M | 2020-05-12 | [ PART ] |
Inscripta Biomanufacturing solutions that replace traditional fossil-based ingredients and products. | Series C Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $55.5M | 2018-02-28 | [ PART ] |
LifeMine LifeMine is a clinical-stage biopharmaceutical company that develops next-generation precision medicines through an innovative drug discovery approach focused on evolutionary insights from fungi, targeting patients in need of breakthrough therapies. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $55M | 2017-09-18 | [ PART ] |